Cordelia Pulmonary Artery Pressure Sensor System (CorPASS)
Endotronix, Inc. · Decision date Oct 16, 2026
What did the FDA approve?
The FDA recorded an approval decision on 2026-10-16 for supplement P230040/S031, submitted by Endotronix, Inc. for the Cordelia Pulmonary Artery Pressure Sensor System (CorPASS). The supplement is classified as a Real-Time Process submission with the reason Labeling Change - Indications/instructions/shelf life/tradename. The device falls under the implantable hemodynamic system category, cardiovascular specialty, product code MOM.
The recorded scope is limited to revisions to the Instructions for Use concerning recommendations for guidewire selections. This action amends labeling within the existing P230040 application rather than constituting a new approval of the whole system. The source record does not include the revised IFU text, the specific guidewire recommendations, or the original approval date, so the content of the change and any clinical implications remain unknown from this data alone.
FDA approval order statement
revisions to the Instructions for Use (IFU) for the Cordelia Pulmonary Artery regarding recommendations for guidewire selections
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 16, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230040/S031
- Regulatory pathway
- PMA supplement
- Applicant
- Endotronix, Inc.
- Product code
- MOM
- Decision code
- APPR
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, hemodynamic, implantable.
- Applicant
- Endotronix, Inc.
- Product code
- MOM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230040. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230040 · Original PMA
Cordella Pulmonary Artery Sensor System (CorPASS)
P230040/S031 received
Application receipt date recorded by FDA.
P230040/S033 · Related supplement
Cordella Pulmonary Artery Sensor System (CorPASS)
P230040/S034 · Related supplement
Cordella Pulmonary Artery Sensor System (CorPASS)
P230040/S031 · FDA decision
Real-Time Process
P230040/S035 · Related supplement
Cordella Pulmonary Artery Sensor System (CorPASS)
P230040/S030 · Related supplement
Cordella Pulmonary Artery Sensor System
Timeline entries are records held by MedtechLedger for P230040. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230040
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Endotronix, Inc. | PMA approval | Jun 20, 2024 | FDA | |
| Endotronix, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Endotronix, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
| Endotronix, Inc. | PMA supplement | Oct 20, 2026 | FDA | |
Cordella Pulmonary Artery Sensor SystemP230040/S030 | Endotronix, Inc. | PMA supplement | Oct 29, 2026 | FDA |
Explore the linked device profile
Other records with product code MOM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Sep 30, 2026 | FDA | |
CardioMEMS PA Sensor and Delivery SystemP100045/S093 | ABBOTT MEDICAL | PMA supplement | Sep 30, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Sep 11, 2026 | FDA | |
| ABBOTT MEDICAL | PMA approval | May 28, 2014 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Endotronix, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1415 W. Diehl Rd., Suite 500w, Naperville, IL, 60563
Sources and methodology
- Original FDA record: P230040/S031
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




